We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
-11.57%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.66B
AUM Growth
-$569M
Cap. Flow
-$51.7M
Cap. Flow %
-3.12%
Top 10 Hldgs %
63.62%
Holding
67
New
7
Increased
4
Reduced
8
Closed
12

Top Buys

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$33.9M
2
IOBT
IO Biotech
IOBT
+$29.1M
3
RLMD icon
Relmada Therapeutics
RLMD
+$19.6M
4
UTRS
Minerva Surgical, Inc. Common Stock
UTRS
+$15.8M
5
OLMA icon
Olema Pharmaceuticals
OLMA
+$9.34M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$47.3M
2
KDMN
Kadmon Holdings, Inc.
KDMN
+$37.3M
3
LEGN icon
Legend Biotech
LEGN
+$12.4M
4
CRIS icon
Curis
CRIS
+$12.2M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 86.32%
2 Financials 9.88%
3 Materials 3.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TIL icon
1
Instil Bio
TIL
$49.4M
$214M 12.88%
624,339
– –
HRMY icon
2
Harmony Biosciences
HRMY
$2.07B
$208M 12.56%
4,884,341
– –
NFH
3
DELISTED
New Frontier Health Corporation Ordinary Shares
NFH
$164M 9.88%
14,300,000
– –
ISEE
4
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$105M 6.34%
6,290,827
+324,300
+5% +$5.32M
ALXO icon
5
ALX Oncology
ALXO
$268M
$90.7M 5.47%
4,220,048
– –
TARS icon
6
Tarsus Pharmaceuticals
TARS
$2.57B
$67.2M 4.05%
2,987,331
– –
AMRS
7
DELISTED
Amyris Inc.
AMRS
$63M 3.8%
11,642,195
– –
ASND icon
8
Ascendis Pharma A/S
ASND
$16.7B
$59.5M 3.59%
442,502
-318,104
-42% -$47.3M
ALGS icon
9
Aligos Therapeutics
ALGS
$26.3M
$42.1M 2.54%
141,881
– –
SRRA
10
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$41.7M 2.51%
1,917,074
– –
GTH
11
DELISTED
Genetron Holdings Limited ADS
GTH
$38.7M 2.33%
2,113,287
– –
SVA
12
DELISTED
Sinovac Biotech, Ltd
SVA
$38.2M 2.3%
5,900,000
– –
VTYX
13
DELISTED
Ventyx Biosciences
VTYX
$35.6M 2.15%
+1,791,275
New +$33.9M
WHWK
14
Whitehawk Therapeutics
WHWK
$182M
$31.5M 1.9%
1,303,390
-123,823
-9% -$3.11M
VRDN icon
15
Viridian Therapeutics
VRDN
$2.15B
$25.7M 1.55%
1,300,000
– –
IMPL
16
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$24.9M 1.5%
2,884,789
– –
AVDL
17
DELISTED
Avadel Pharmaceuticals
AVDL
$23.7M 1.43%
2,937,093
– –
KALV
18
DELISTED
KalVista Pharmaceuticals
KALV
$20.3M 1.22%
1,533,559
-108,354
-7% -$1.72M
RLMD icon
19
Relmada Therapeutics
RLMD
$549M
$19.9M 1.2%
+882,352
New +$19.6M
IOBT
20
DELISTED
IO Biotech
IOBT
$19.3M 1.16%
+3,015,545
New +$29.1M
BOLT icon
21
Bolt Biotherapeutics
BOLT
$7.72M
$19M 1.14%
193,565
– –
TERN
22
DELISTED
Terns Pharmaceuticals
TERN
$18.9M 1.14%
2,675,133
– –
CLDX icon
23
Celldex Therapeutics
CLDX
$2.79B
$18.7M 1.13%
484,453
– –
VRNA
24
DELISTED
Verona Pharma
VRNA
$18.5M 1.11%
2,749,918
– –
COGT icon
25
Cogent Biosciences
COGT
$6.95B
$16.5M 0.99%
1,920,941
+500,000
+35% +$4.35M
1
2 3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Vivo Capital held 67 positions worth $1.66B, down 26% from $2.23B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Vivo Capital withdrew a net $51.7M in Q4 2021, closing 12 positions and reducing 8 holdings. Its most notable exit was Kadmon Holdings, Inc., an estimated $37.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 86% a quarter earlier, followed by Financials and Materials.

Against the trend, Vivo Capital opened a new position in Ventyx Biosciences worth $35.6M.

  • Vivo Capital's largest Q4 2021 buy was Ventyx Biosciences: 1,791,275 shares worth $35.6M.
  • Vivo Capital added most to Olema Pharmaceuticals in Q4 2021, an estimated $9.34M increase.
  • Vivo Capital's biggest Q4 2021 reduction was Ascendis Pharma A/S, cutting an estimated $47.3M.
  • Vivo Capital fully exited Kadmon Holdings, Inc. in Q4 2021, selling an estimated $37.3M.
  • Vivo Capital's ten largest holdings make up 64% of its $1.66B portfolio in Q4 2021.
  • Vivo Capital opened 7 new positions and closed 12 in Q4 2021.
  • Vivo Capital's portfolio value fell 26% quarter-over-quarter to $1.66B.

Based on Vivo Capital's 13F filing for Q4 2021, filed 11 Feb 2022.